In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss.

If you haven’t done so already, be sure to check out our CAR T episode.

Content:

- What are bispecific T-cell engagers?

- How are they different than CAR T?

- A discussion of the pivotal MajesTEC-3 trial (NEJM 2025)

- What are key side effects?

- How to sequence CAR T vs. bispecific T-cell engagers?

** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration.

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)

The Fellow on Call: The Heme/Onc Podcast

Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)